MIG AG

MIG Verwaltungs AG is a Munich-based venture capital firm that focuses on investing in small and medium-sized enterprises across various industries, with a particular emphasis on life sciences and technology. Established in 2004, the firm targets investments in sectors such as artificial intelligence, machine learning, quantum technology, digitalization, medical technology, digital health, and biopharmaceuticals. MIG AG primarily invests in companies located in Germany, Austria, and Switzerland, with a minimum investment threshold of €0.1 million. The firm typically holds its investments for a duration of four to eight years before seeking an exit. Through its strategic investments, MIG AG aims to foster innovation and contribute to advancements in technology and healthcare.

Klaus Feix

Venture Partner

Matthias Guth

Venture Partner

Oliver Kahl

Principal

Andreas Kastenbauer

Venture Partner

Jürgen Kosch

General Partner

Matthias Kromayer

General Partner

Frederick Michna

Principal

Michael Motschmann

General Partner

Axel Thierauf

Venture Partner

Fei Tian

Principal

89 past transactions

Innatera

Series A in 2024
Innatera is an innovative developer of ultra-low power neuromorphic processors designed to enhance the efficiency of sensor data processing. Established in 2018 as a spin-off from the Delft University of Technology, the company focuses on creating processors that replicate the brain's mechanisms for sensory perception. Utilizing a novel continuous-time analog-mixed signal processing architecture, Innatera's chips can process sensor data up to 100 times faster while consuming up to 500 times less energy compared to traditional processors. This technology enables businesses to access and analyze sensor data more effectively, positioning Innatera as a leader in the field of energy-efficient computing solutions.

Hawkcell

Series A in 2024
HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. The company utilizes a non-ionizing three-dimensional (3D) imaging approach, employing specialized MRI sensors designed to accommodate various animal morphologies. By adapting human MRI technology for animal diagnostics, HawkCell provides sustainable systems enhanced with artificial intelligence algorithms. This innovation allows veterinary clinics and research labs to obtain precise and insightful imaging, facilitating improved animal healthcare and scientific exploration.

Look Up Space

Seed Round in 2023
Look Up Space specializes in providing high-quality space safety and security data and services designed to assist organizations in effectively managing space-related risks. The company utilizes a dedicated, sovereign sensor network combined with advanced data processing capabilities to deliver real-time information. This approach enables businesses to access critical data that supports their growth while simplifying the complexities associated with space safety and security.

AMSilk

Series C in 2023
AMSilk GmbH, founded in 2008 and based in Munich, Germany, specializes in producing spider silk proteins and other biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film for protective coatings, and biosteel spider silk fibers. Additionally, AMSilk provides wound care products such as SanaSilk, designed to protect the skin, and spider silk-based solutions for surgical applications. Their product portfolio also includes spider silk protein beads and coatings for medical technology, as well as nonwovens for use in filters, wound dressings, and specialty textiles. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company employs a patented biotechnological process to create biodegradable polymers from silk proteins, enabling the production of various forms such as powders, hydrogels, and fibers that are environmentally friendly.

talpasolutions

Series B in 2023
talpasolutions a predictive SaaS analytics provider for the mining industry that helps companies optimize machine performance, reduce breakdowns, and improve safety by making data more understandable. talpasolutions makes it possible for operators and machine manufacturers in heavy industry to use machine data that would have otherwise been lost. talpasolutions concentrates on building visualization and analysis applications for the industrial internet. In the first step, large amounts of data from the machines are recorded. Comprehendable visualizations allow for different stakeholders to understand relationships based on sensor data and contextual data and to react to critical information, which would otherwise have been buried in the data transfer. In the second step the newest predictive models are applied to eliminate events such as errors and the breakdown of machines critical to the process. This increases not only the availability but also the workload of the machines. talpasolutions has built a network out of industry partners to develop solutions that stretch across various sectors and unify industry experience, data science, and workflow connectivity. Using predictive instructions our platform recognizes problems before they occur and supports users with workflow-based processes. Our applications make it possible to collect performance data from machines in order to recommend optimal fleet combinations for respective scenarios to customers. This leads to more operating hours, higher efficiency, and an improved lifetime value of the machines.

Mbiomics

Series A in 2023
Mbiomics is a biotechnology company focused on microbiome research, diagnostics, and therapeutics. It has developed a high-throughput, low-cost platform that allows for dynamic and real-time analysis and quantification of the human gut microbiome. By providing informed precision diagnostics and targeted therapies, Mbiomics aims to enhance patient outcomes and promote healthier living through innovative approaches.

KEWAZO

Series A in 2023
KEWAZO GmbH, founded in 2016 and based in Gilching, Germany, specializes in developing robotic systems for the construction industry, specifically aimed at enhancing material transport for scaffolding companies and industrial service providers. The company's flagship product, the robotic material hoist LIFTBOT, automates the flow of materials both vertically and horizontally on construction sites, significantly reducing labor costs and addressing labor shortages while improving safety. By integrating these robotic platforms on-site, KEWAZO not only facilitates just-in-time and just-in-place delivery of scaffolding parts during assembly but also collects operational data. This data is made available to clients through a comprehensive analytics platform, enabling more proactive management of projects and overall company operations.

Inbolt

Seed Round in 2022
Inbolt specializes in developing advanced vision systems for industrial robots, aimed at enhancing decision-making capabilities in various environments. By utilizing artificial intelligence and 3D vision, Inbolt's technology provides adaptive real-time guidance for robots, allowing them to operate more intelligently. Additionally, the company's vision-based tools facilitate the automation of complex tasks in unstructured settings, offering real-time quality control for manual operations like torquing, drilling, and riveting. This innovation not only reduces the incidence of faulty operations but also significantly improves overall quality control in industrial processes.

GoBolt

Series B in 2021
Founded in 2017, GoBolt is a technology company building the first sustainable and vertically integrated supply chain network that partners with merchants to deliver a complete end-to-end customer experience. By operating as an extension of each merchant’s team, GoBolt provides reliable warehousing, pick and pack, shipping, and last mile delivery. With a growing network of warehouses across North America and a suite of proprietary apps designed and supported by an in-house engineering team, GoBolt unlocks enhanced transparency and control for merchants. The company’s focus on customer-centricity is further driven by a deep commitment to sustainability. GoBolt’s investment in its electric vehicle fleet and sustainability partnerships is a testament to the company’s mission to provide carbon neutral deliveries. For more information, visit GoBolt.com.

Efficient Energy

Series A in 2021
Efficient Energy GmbH, based in Feldkirchen, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and residential applications. The company is known for its innovative eChiller, which utilizes pure water as a refrigerant, effectively eliminating the need for harmful fluorinated refrigerants. This clean compression refrigeration unit is designed for various cooling needs, including data centers, server rooms, and industrial processes, with cooling capacities ranging from 35 kW to 120 kW. In addition to its products, Efficient Energy offers a range of services, including consulting, planning, installation, and energy efficiency optimization. The company's pioneering technology has garnered recognition, receiving several awards, including the European Business Award for the Environment and recognition in the Deloitte Technology Fast 50. Efficient Energy aims to provide sustainable, efficient, and cost-effective cooling solutions to meet the growing regulatory challenges in the refrigeration industry.

iOmx Therapeutics

Series B in 2021
iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The firm focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx Therapeutics has identified several new targets and examined their mechanisms of action. The company's foundation is built upon the principles of cancer immune-checkpoint therapy, which aims to overcome the resistance mechanisms that tumors utilize to evade immune attacks. These resistance mechanisms often involve specific cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

KEWAZO

Series A in 2021
KEWAZO GmbH, founded in 2016 and based in Gilching, Germany, specializes in developing robotic systems for the construction industry, specifically aimed at enhancing material transport for scaffolding companies and industrial service providers. The company's flagship product, the robotic material hoist LIFTBOT, automates the flow of materials both vertically and horizontally on construction sites, significantly reducing labor costs and addressing labor shortages while improving safety. By integrating these robotic platforms on-site, KEWAZO not only facilitates just-in-time and just-in-place delivery of scaffolding parts during assembly but also collects operational data. This data is made available to clients through a comprehensive analytics platform, enabling more proactive management of projects and overall company operations.

AMSilk

Series C in 2021
AMSilk GmbH, founded in 2008 and based in Munich, Germany, specializes in producing spider silk proteins and other biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film for protective coatings, and biosteel spider silk fibers. Additionally, AMSilk provides wound care products such as SanaSilk, designed to protect the skin, and spider silk-based solutions for surgical applications. Their product portfolio also includes spider silk protein beads and coatings for medical technology, as well as nonwovens for use in filters, wound dressings, and specialty textiles. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company employs a patented biotechnological process to create biodegradable polymers from silk proteins, enabling the production of various forms such as powders, hydrogels, and fibers that are environmentally friendly.

GoBolt

Venture Round in 2021
Founded in 2017, GoBolt is a technology company building the first sustainable and vertically integrated supply chain network that partners with merchants to deliver a complete end-to-end customer experience. By operating as an extension of each merchant’s team, GoBolt provides reliable warehousing, pick and pack, shipping, and last mile delivery. With a growing network of warehouses across North America and a suite of proprietary apps designed and supported by an in-house engineering team, GoBolt unlocks enhanced transparency and control for merchants. The company’s focus on customer-centricity is further driven by a deep commitment to sustainability. GoBolt’s investment in its electric vehicle fleet and sustainability partnerships is a testament to the company’s mission to provide carbon neutral deliveries. For more information, visit GoBolt.com.

Liva Healthcare

Series B in 2021
Liva Healthcare is a digital health coaching platform that focuses on lifestyle and disease management, particularly for chronic illnesses such as Type 2 diabetes, obesity, and heart disease. The platform provides personalized health coaching through an intuitive app that fosters collaboration between coaches, general practitioners, and patients. It is designed to engage users over a period of nine to 18 months, promoting sustainable behavior change. Liva Healthcare's services are multilingual and accessible to diverse socio-economic groups, allowing coaches to effectively manage up to 500 patients simultaneously while maintaining quality outcomes. The platform includes features such as tailored health plans, goal tracking, and self-monitoring, making it suitable for both individual and group interventions. Liva Healthcare serves various clients, including public healthcare systems and private insurance companies, and offers its solutions as a white-label SaaS or turn-key product. The company operates offices in Copenhagen, Denmark, and London, UK.

German Bionic

Series A in 2020
German Bionic is a manufacturer of innovative exoskeletons designed to enhance efficiency and productivity in industrial settings. The company has developed the Cray X, the world's first connected exoskeleton, which integrates with Smart Factory systems to self-learn and reinforce proper lifting techniques, thereby preventing incorrect posture. This technology serves as an intelligent interface between humans and machines, providing valuable data that demonstrates its effectiveness in protecting workers' health and significantly reducing the risk of accidents and strain-related injuries. Supported by prominent investors such as Samsung Catalyst Fund and Storm Ventures, German Bionic has received numerous accolades, including the German Entrepreneur Award and the Automatica Award, highlighting its impact on improving workplace safety and operational processes.

Innatera

Seed Round in 2020
Innatera is an innovative developer of ultra-low power neuromorphic processors designed to enhance the efficiency of sensor data processing. Established in 2018 as a spin-off from the Delft University of Technology, the company focuses on creating processors that replicate the brain's mechanisms for sensory perception. Utilizing a novel continuous-time analog-mixed signal processing architecture, Innatera's chips can process sensor data up to 100 times faster while consuming up to 500 times less energy compared to traditional processors. This technology enables businesses to access and analyze sensor data more effectively, positioning Innatera as a leader in the field of energy-efficient computing solutions.

Efficient Energy

Venture Round in 2020
Efficient Energy GmbH, based in Feldkirchen, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and residential applications. The company is known for its innovative eChiller, which utilizes pure water as a refrigerant, effectively eliminating the need for harmful fluorinated refrigerants. This clean compression refrigeration unit is designed for various cooling needs, including data centers, server rooms, and industrial processes, with cooling capacities ranging from 35 kW to 120 kW. In addition to its products, Efficient Energy offers a range of services, including consulting, planning, installation, and energy efficiency optimization. The company's pioneering technology has garnered recognition, receiving several awards, including the European Business Award for the Environment and recognition in the Deloitte Technology Fast 50. Efficient Energy aims to provide sustainable, efficient, and cost-effective cooling solutions to meet the growing regulatory challenges in the refrigeration industry.

KEWAZO

Seed Round in 2020
KEWAZO GmbH, founded in 2016 and based in Gilching, Germany, specializes in developing robotic systems for the construction industry, specifically aimed at enhancing material transport for scaffolding companies and industrial service providers. The company's flagship product, the robotic material hoist LIFTBOT, automates the flow of materials both vertically and horizontally on construction sites, significantly reducing labor costs and addressing labor shortages while improving safety. By integrating these robotic platforms on-site, KEWAZO not only facilitates just-in-time and just-in-place delivery of scaffolding parts during assembly but also collects operational data. This data is made available to clients through a comprehensive analytics platform, enabling more proactive management of projects and overall company operations.

Biocrates Life Sciences

Venture Round in 2019
Biocrates Life Sciences AG is a biotechnology firm based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions for the discovery and validation of biomarkers related to complex diseases. Founded in 2002, the company offers mass-spectrometry based kits and services that quantitatively analyze a wide range of endogenous metabolites, providing insights into disease pathways and metabolic signatures. Its products are applicable in various fields, including oncology, cardiovascular health, neurodegenerative disorders, and diabetes, among others. Biocrates' metabolomics platform features an automated sample preparation workflow and advanced software for sample management, data collection, and analysis, enabling the rapid identification of hundreds of metabolites. The company's solutions are distributed through authorized partners in multiple regions, including the Middle East, Europe, and Scandinavian countries, supporting both pre-clinical and clinical research efforts.

IQM Quantum Computers

Seed Round in 2019
IQM is the pan-European leader in building quantum computers. IQM delivers on-premises quantum computers for supercomputing data centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 190+ employees with offices in Paris, Madrid, Munich, and Espoo.

Liva Healthcare

Series A in 2019
Liva Healthcare is a digital health coaching platform that focuses on lifestyle and disease management, particularly for chronic illnesses such as Type 2 diabetes, obesity, and heart disease. The platform provides personalized health coaching through an intuitive app that fosters collaboration between coaches, general practitioners, and patients. It is designed to engage users over a period of nine to 18 months, promoting sustainable behavior change. Liva Healthcare's services are multilingual and accessible to diverse socio-economic groups, allowing coaches to effectively manage up to 500 patients simultaneously while maintaining quality outcomes. The platform includes features such as tailored health plans, goal tracking, and self-monitoring, making it suitable for both individual and group interventions. Liva Healthcare serves various clients, including public healthcare systems and private insurance companies, and offers its solutions as a white-label SaaS or turn-key product. The company operates offices in Copenhagen, Denmark, and London, UK.

Efficient Energy

Venture Round in 2019
Efficient Energy GmbH, based in Feldkirchen, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and residential applications. The company is known for its innovative eChiller, which utilizes pure water as a refrigerant, effectively eliminating the need for harmful fluorinated refrigerants. This clean compression refrigeration unit is designed for various cooling needs, including data centers, server rooms, and industrial processes, with cooling capacities ranging from 35 kW to 120 kW. In addition to its products, Efficient Energy offers a range of services, including consulting, planning, installation, and energy efficiency optimization. The company's pioneering technology has garnered recognition, receiving several awards, including the European Business Award for the Environment and recognition in the Deloitte Technology Fast 50. Efficient Energy aims to provide sustainable, efficient, and cost-effective cooling solutions to meet the growing regulatory challenges in the refrigeration industry.

KONUX

Series B in 2019
KONUX GmbH, founded in 2014 and based in Munich, Germany, specializes in the development of Industrial Internet of Things (IIoT) solutions that integrate smart sensor systems with artificial intelligence-based analytics. The company's offerings include switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and predictive analytics, all aimed at enhancing railway and industrial operations. By providing real-time monitoring and predictive maintenance capabilities, KONUX helps clients improve the reliability, capacity, and cost-efficiency of their railway systems. The company has expanded its reach across multiple countries in Europe and Asia and has been recognized by the World Economic Forum as one of the world's most innovative start-ups. With over $130 million raised from leading investors, KONUX is committed to modernizing railroad operations and contributing to a sustainable future in mobility.

NavVis

Series C in 2018
NavVis is a technology company based in Munich, Germany, specializing in indoor spatial intelligence and digital twin solutions. The company offers mobile mapping systems that utilize simultaneous localization and mapping (SLAM) technology to generate high-quality, survey-grade data quickly and efficiently. Its platform is designed to assist service providers and enterprises in capturing and sharing the built environment as photorealistic digital twins, enabling better operational decisions and increased productivity. NavVis's digital factory solutions facilitate improved business processes and profitability for clients in industries such as surveying, architecture, engineering, construction, and manufacturing. With additional offices in the United States and China, NavVis serves a global customer base, providing tools for accurate 3D mapping and immersive visualization of industrial facilities.

advanceCOR

Venture Round in 2018
advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases. Its products include Revacept, a human Fc fusion protein, which prevents the local activation of platelets at sites of vascular injury; COR-2, a recombinant protein that interferes with the generation of foam cells; and COR-3, a recombinant protein, which specifically binds to atherosclerotic plaques, and then bi-specifically binds to circulating progenitor cells to trap the endogenously occurring progenitor cells for accelerated plaque healing.

KEWAZO

Seed Round in 2018
KEWAZO GmbH, founded in 2016 and based in Gilching, Germany, specializes in developing robotic systems for the construction industry, specifically aimed at enhancing material transport for scaffolding companies and industrial service providers. The company's flagship product, the robotic material hoist LIFTBOT, automates the flow of materials both vertically and horizontally on construction sites, significantly reducing labor costs and addressing labor shortages while improving safety. By integrating these robotic platforms on-site, KEWAZO not only facilitates just-in-time and just-in-place delivery of scaffolding parts during assembly but also collects operational data. This data is made available to clients through a comprehensive analytics platform, enabling more proactive management of projects and overall company operations.

KONUX

Series B in 2018
KONUX GmbH, founded in 2014 and based in Munich, Germany, specializes in the development of Industrial Internet of Things (IIoT) solutions that integrate smart sensor systems with artificial intelligence-based analytics. The company's offerings include switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and predictive analytics, all aimed at enhancing railway and industrial operations. By providing real-time monitoring and predictive maintenance capabilities, KONUX helps clients improve the reliability, capacity, and cost-efficiency of their railway systems. The company has expanded its reach across multiple countries in Europe and Asia and has been recognized by the World Economic Forum as one of the world's most innovative start-ups. With over $130 million raised from leading investors, KONUX is committed to modernizing railroad operations and contributing to a sustainable future in mobility.

BioNTech

Series A in 2018
BioNTech is a biotechnology company based in Germany that specializes in developing innovative therapies for cancer and infectious diseases, including COVID-19. The company is known for its focus on individualized immunotherapy and has a diverse oncology pipeline that features various classes of drugs, such as mRNA-based therapeutics that encode antigens and neoantigens, as well as cytokines, antibodies, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech's notable achievement includes the commercialization of its COVID-19 vaccine, Comirnaty. Additionally, the company collaborates with several major pharmaceutical firms, enhancing its capabilities and reach in the biopharmaceutical industry.

Siltectra

Series B in 2017
Siltectra GmbH, based in Dresden, Germany, specializes in advanced laser-based wafering technology solutions for semiconductor manufacturers. Founded in 2010, the company focuses on kerfless wafering, a method that allows for the separation of wafers from semiconductor materials like silicon carbide, gallium nitride, and sapphire without material loss. This innovative technology can be applied across various industries, particularly in solar inverters and other electronic devices, offering significant performance and cost advantages. Siltectra operates as a subsidiary of Infineon Technologies AG, providing critical services that enhance the efficiency of the global semiconductor industry.

Hemovent

Series A in 2017
​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop an innovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.

Efficient Energy

Venture Round in 2017
Efficient Energy GmbH, based in Feldkirchen, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and residential applications. The company is known for its innovative eChiller, which utilizes pure water as a refrigerant, effectively eliminating the need for harmful fluorinated refrigerants. This clean compression refrigeration unit is designed for various cooling needs, including data centers, server rooms, and industrial processes, with cooling capacities ranging from 35 kW to 120 kW. In addition to its products, Efficient Energy offers a range of services, including consulting, planning, installation, and energy efficiency optimization. The company's pioneering technology has garnered recognition, receiving several awards, including the European Business Award for the Environment and recognition in the Deloitte Technology Fast 50. Efficient Energy aims to provide sustainable, efficient, and cost-effective cooling solutions to meet the growing regulatory challenges in the refrigeration industry.

LXP Group

Series A in 2017
LXP Group GmbH, founded in 2009 and based in Marienwerder, Germany, specializes in the development of the LX-Process, a technology that effectively cracks second-generation (2G) biomass. This innovative process enables the production of 2G ethanol, bio-based chemicals, and natural lignin, addressing challenges in bio-processing, particularly the inhibition issues found in existing pre-treatment methods. The LX-Process is versatile, suitable for large-scale ethanol manufacturing while also being adaptable for retrofitting smaller, decentralized biogas plants. By utilizing agricultural residues, LXP Group contributes to the sustainable production of renewable energy and bio-based products. Formerly known as MaxBiogas GmbH, the company continues to advance its technology to enhance the efficiency and economic viability of biomass conversion.

Siltectra

Series B in 2017
Siltectra GmbH, based in Dresden, Germany, specializes in advanced laser-based wafering technology solutions for semiconductor manufacturers. Founded in 2010, the company focuses on kerfless wafering, a method that allows for the separation of wafers from semiconductor materials like silicon carbide, gallium nitride, and sapphire without material loss. This innovative technology can be applied across various industries, particularly in solar inverters and other electronic devices, offering significant performance and cost advantages. Siltectra operates as a subsidiary of Infineon Technologies AG, providing critical services that enhance the efficiency of the global semiconductor industry.

KONUX

Series A in 2017
KONUX GmbH, founded in 2014 and based in Munich, Germany, specializes in the development of Industrial Internet of Things (IIoT) solutions that integrate smart sensor systems with artificial intelligence-based analytics. The company's offerings include switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and predictive analytics, all aimed at enhancing railway and industrial operations. By providing real-time monitoring and predictive maintenance capabilities, KONUX helps clients improve the reliability, capacity, and cost-efficiency of their railway systems. The company has expanded its reach across multiple countries in Europe and Asia and has been recognized by the World Economic Forum as one of the world's most innovative start-ups. With over $130 million raised from leading investors, KONUX is committed to modernizing railroad operations and contributing to a sustainable future in mobility.

AFFiRiS

Venture Round in 2016
AFFiRiS AG is a Vienna-based company specializing in the development and manufacture of peptide-based vaccines aimed at treating chronic diseases that have significant unmet medical needs. Established in 2003, the company's portfolio includes vaccines targeting a range of conditions such as Alzheimer’s disease, Parkinson’s disease, atherosclerosis, hypertension, diabetes, psoriasis, allergies, asthma, and Huntington’s disease, among others. By focusing on tailored therapeutic solutions, AFFiRiS aims to address critical health challenges through innovative vaccine technology.

Siltectra

Series B in 2016
Siltectra GmbH, based in Dresden, Germany, specializes in advanced laser-based wafering technology solutions for semiconductor manufacturers. Founded in 2010, the company focuses on kerfless wafering, a method that allows for the separation of wafers from semiconductor materials like silicon carbide, gallium nitride, and sapphire without material loss. This innovative technology can be applied across various industries, particularly in solar inverters and other electronic devices, offering significant performance and cost advantages. Siltectra operates as a subsidiary of Infineon Technologies AG, providing critical services that enhance the efficiency of the global semiconductor industry.

KONUX

Series A in 2016
KONUX GmbH, founded in 2014 and based in Munich, Germany, specializes in the development of Industrial Internet of Things (IIoT) solutions that integrate smart sensor systems with artificial intelligence-based analytics. The company's offerings include switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and predictive analytics, all aimed at enhancing railway and industrial operations. By providing real-time monitoring and predictive maintenance capabilities, KONUX helps clients improve the reliability, capacity, and cost-efficiency of their railway systems. The company has expanded its reach across multiple countries in Europe and Asia and has been recognized by the World Economic Forum as one of the world's most innovative start-ups. With over $130 million raised from leading investors, KONUX is committed to modernizing railroad operations and contributing to a sustainable future in mobility.

Hemovent

Series A in 2016
​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop an innovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.

NavVis

Series B in 2015
NavVis is a technology company based in Munich, Germany, specializing in indoor spatial intelligence and digital twin solutions. The company offers mobile mapping systems that utilize simultaneous localization and mapping (SLAM) technology to generate high-quality, survey-grade data quickly and efficiently. Its platform is designed to assist service providers and enterprises in capturing and sharing the built environment as photorealistic digital twins, enabling better operational decisions and increased productivity. NavVis's digital factory solutions facilitate improved business processes and profitability for clients in industries such as surveying, architecture, engineering, construction, and manufacturing. With additional offices in the United States and China, NavVis serves a global customer base, providing tools for accurate 3D mapping and immersive visualization of industrial facilities.

Efficient Energy

Venture Round in 2015
Efficient Energy GmbH, based in Feldkirchen, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and residential applications. The company is known for its innovative eChiller, which utilizes pure water as a refrigerant, effectively eliminating the need for harmful fluorinated refrigerants. This clean compression refrigeration unit is designed for various cooling needs, including data centers, server rooms, and industrial processes, with cooling capacities ranging from 35 kW to 120 kW. In addition to its products, Efficient Energy offers a range of services, including consulting, planning, installation, and energy efficiency optimization. The company's pioneering technology has garnered recognition, receiving several awards, including the European Business Award for the Environment and recognition in the Deloitte Technology Fast 50. Efficient Energy aims to provide sustainable, efficient, and cost-effective cooling solutions to meet the growing regulatory challenges in the refrigeration industry.

Siltectra

Series B in 2015
Siltectra GmbH, based in Dresden, Germany, specializes in advanced laser-based wafering technology solutions for semiconductor manufacturers. Founded in 2010, the company focuses on kerfless wafering, a method that allows for the separation of wafers from semiconductor materials like silicon carbide, gallium nitride, and sapphire without material loss. This innovative technology can be applied across various industries, particularly in solar inverters and other electronic devices, offering significant performance and cost advantages. Siltectra operates as a subsidiary of Infineon Technologies AG, providing critical services that enhance the efficiency of the global semiconductor industry.

Protagen

Venture Round in 2014
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Siltectra

Series A in 2014
Siltectra GmbH, based in Dresden, Germany, specializes in advanced laser-based wafering technology solutions for semiconductor manufacturers. Founded in 2010, the company focuses on kerfless wafering, a method that allows for the separation of wafers from semiconductor materials like silicon carbide, gallium nitride, and sapphire without material loss. This innovative technology can be applied across various industries, particularly in solar inverters and other electronic devices, offering significant performance and cost advantages. Siltectra operates as a subsidiary of Infineon Technologies AG, providing critical services that enhance the efficiency of the global semiconductor industry.

Isarna Therapeutics

Venture Round in 2014
Isarna Therapeutics is focused on developing selective TGF-β inhibitors aimed at treating ophthalmic diseases, fibrotic conditions, and cancer. The company is advancing a unique pipeline that includes novel oligonucleotides and combination therapies designed to enhance clinical responses and improve patient outcomes. Through its innovative approach, Isarna Therapeutics seeks to address significant unmet medical needs in these areas.

Isarna Therapeutics

Venture Round in 2014
Isarna Therapeutics is focused on developing selective TGF-β inhibitors aimed at treating ophthalmic diseases, fibrotic conditions, and cancer. The company is advancing a unique pipeline that includes novel oligonucleotides and combination therapies designed to enhance clinical responses and improve patient outcomes. Through its innovative approach, Isarna Therapeutics seeks to address significant unmet medical needs in these areas.

Ganymed Pharmaceuticals

Series E in 2013
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

SuppreMol

Series D in 2013
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Efficient Energy

Venture Round in 2013
Efficient Energy GmbH, based in Feldkirchen, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and residential applications. The company is known for its innovative eChiller, which utilizes pure water as a refrigerant, effectively eliminating the need for harmful fluorinated refrigerants. This clean compression refrigeration unit is designed for various cooling needs, including data centers, server rooms, and industrial processes, with cooling capacities ranging from 35 kW to 120 kW. In addition to its products, Efficient Energy offers a range of services, including consulting, planning, installation, and energy efficiency optimization. The company's pioneering technology has garnered recognition, receiving several awards, including the European Business Award for the Environment and recognition in the Deloitte Technology Fast 50. Efficient Energy aims to provide sustainable, efficient, and cost-effective cooling solutions to meet the growing regulatory challenges in the refrigeration industry.

Siltectra

Series A in 2013
Siltectra GmbH, based in Dresden, Germany, specializes in advanced laser-based wafering technology solutions for semiconductor manufacturers. Founded in 2010, the company focuses on kerfless wafering, a method that allows for the separation of wafers from semiconductor materials like silicon carbide, gallium nitride, and sapphire without material loss. This innovative technology can be applied across various industries, particularly in solar inverters and other electronic devices, offering significant performance and cost advantages. Siltectra operates as a subsidiary of Infineon Technologies AG, providing critical services that enhance the efficiency of the global semiconductor industry.

SuppreMol

Series D in 2012
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Siltectra

Seed Round in 2012
Siltectra GmbH, based in Dresden, Germany, specializes in advanced laser-based wafering technology solutions for semiconductor manufacturers. Founded in 2010, the company focuses on kerfless wafering, a method that allows for the separation of wafers from semiconductor materials like silicon carbide, gallium nitride, and sapphire without material loss. This innovative technology can be applied across various industries, particularly in solar inverters and other electronic devices, offering significant performance and cost advantages. Siltectra operates as a subsidiary of Infineon Technologies AG, providing critical services that enhance the efficiency of the global semiconductor industry.

NFON

Venture Round in 2012
NFON is a Munich, Germany-based provider of outsourced telephone systems. nfon's outsourced telephone systems, called IP Centrex, are offered as a complete package from a single source. Operated by a fully redundant, high-performance computer centre and with more than 100 functions, the solution is designed to enable companies of all sizes to save up to 50% percent of the costs for a conventional phone system.

AFFiRiS

Venture Round in 2011
AFFiRiS AG is a Vienna-based company specializing in the development and manufacture of peptide-based vaccines aimed at treating chronic diseases that have significant unmet medical needs. Established in 2003, the company's portfolio includes vaccines targeting a range of conditions such as Alzheimer’s disease, Parkinson’s disease, atherosclerosis, hypertension, diabetes, psoriasis, allergies, asthma, and Huntington’s disease, among others. By focusing on tailored therapeutic solutions, AFFiRiS aims to address critical health challenges through innovative vaccine technology.

IDENT Technology

Venture Round in 2011
IDENT Technology AG specializes in technology solutions for near-field communication and gesture-controlled human-machine interfaces. Based in Wessling, Germany, the company offers a range of products under its SKINPLEX brand, including SKINPLEX GestIC for gesture detection, a zeropower sensor system for touchless applications, and an ultra-low-power proximity system designed to manage device power based on user proximity. These technologies are particularly relevant for various industries, including consumer electronics, gaming, healthcare, telecommunications, and automotive. Founded in 2002, IDENT Technology focuses on providing innovative solutions that enhance user interaction through advanced sensing and identification capabilities.

Isarna Therapeutics

Venture Round in 2011
Isarna Therapeutics is focused on developing selective TGF-β inhibitors aimed at treating ophthalmic diseases, fibrotic conditions, and cancer. The company is advancing a unique pipeline that includes novel oligonucleotides and combination therapies designed to enhance clinical responses and improve patient outcomes. Through its innovative approach, Isarna Therapeutics seeks to address significant unmet medical needs in these areas.

CYNORA

Series A in 2011
CYNORA GmbH, founded in 2008 and headquartered in Bruchsal, Germany, specializes in the development and manufacture of organic electronics, particularly organic light-emitting diodes (OLEDs). The company focuses on creating highly efficient blue and green emitter systems utilizing Thermally Activated Delayed Fluorescence (TADF) technology. This innovative approach allows for the conversion of triplet excitons into light, thereby enhancing power efficiency and reducing electrical stress within OLED devices. As demand for thin, flexible screens with improved image quality and lower power consumption rises, CYNORA aims to provide added value to OLED producers with its iridium-free, purely organic emitter solutions. By addressing the challenges faced in developing stable and efficient blue emitters, CYNORA is positioned to support advancements in the AMOLED market and contribute to the evolution of display technology.

AMSilk

Series B in 2011
AMSilk GmbH, founded in 2008 and based in Munich, Germany, specializes in producing spider silk proteins and other biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film for protective coatings, and biosteel spider silk fibers. Additionally, AMSilk provides wound care products such as SanaSilk, designed to protect the skin, and spider silk-based solutions for surgical applications. Their product portfolio also includes spider silk protein beads and coatings for medical technology, as well as nonwovens for use in filters, wound dressings, and specialty textiles. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company employs a patented biotechnological process to create biodegradable polymers from silk proteins, enabling the production of various forms such as powders, hydrogels, and fibers that are environmentally friendly.

Efficient Energy

Venture Round in 2011
Efficient Energy GmbH, based in Feldkirchen, Germany, specializes in the development, manufacturing, and distribution of environmentally friendly refrigeration systems for both industrial and residential applications. The company is known for its innovative eChiller, which utilizes pure water as a refrigerant, effectively eliminating the need for harmful fluorinated refrigerants. This clean compression refrigeration unit is designed for various cooling needs, including data centers, server rooms, and industrial processes, with cooling capacities ranging from 35 kW to 120 kW. In addition to its products, Efficient Energy offers a range of services, including consulting, planning, installation, and energy efficiency optimization. The company's pioneering technology has garnered recognition, receiving several awards, including the European Business Award for the Environment and recognition in the Deloitte Technology Fast 50. Efficient Energy aims to provide sustainable, efficient, and cost-effective cooling solutions to meet the growing regulatory challenges in the refrigeration industry.

SuppreMol

Series C in 2010
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Corimmun

Series B in 2010
Corimmun is a clinical drug development company based in Martinsried, near Munich, Germany. The company specializes in creating innovative therapeutics and diagnostics aimed at treating heart and vascular diseases, particularly those that currently have unmet medical needs. Corimmun's expertise encompasses the entire spectrum of drug development, from initial research through to commercialization, positioning it as a key player in the field of cardiovascular therapeutics.

immatics biotechnologies

Series C in 2010
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

IDENT Technology

Venture Round in 2010
IDENT Technology AG specializes in technology solutions for near-field communication and gesture-controlled human-machine interfaces. Based in Wessling, Germany, the company offers a range of products under its SKINPLEX brand, including SKINPLEX GestIC for gesture detection, a zeropower sensor system for touchless applications, and an ultra-low-power proximity system designed to manage device power based on user proximity. These technologies are particularly relevant for various industries, including consumer electronics, gaming, healthcare, telecommunications, and automotive. Founded in 2002, IDENT Technology focuses on providing innovative solutions that enhance user interaction through advanced sensing and identification capabilities.

Biocrates Life Sciences

Venture Round in 2010
Biocrates Life Sciences AG is a biotechnology firm based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions for the discovery and validation of biomarkers related to complex diseases. Founded in 2002, the company offers mass-spectrometry based kits and services that quantitatively analyze a wide range of endogenous metabolites, providing insights into disease pathways and metabolic signatures. Its products are applicable in various fields, including oncology, cardiovascular health, neurodegenerative disorders, and diabetes, among others. Biocrates' metabolomics platform features an automated sample preparation workflow and advanced software for sample management, data collection, and analysis, enabling the rapid identification of hundreds of metabolites. The company's solutions are distributed through authorized partners in multiple regions, including the Middle East, Europe, and Scandinavian countries, supporting both pre-clinical and clinical research efforts.

PDC Biotech

Series A in 2010
PDC Biotech GmbH is a biotechnology company based in Vienna, Austria, specializing in the development of innovative therapeutics for the treatment of preterm labor and primary dysmenorrhea, both of which represent significant unmet medical needs. Established in 2008, PDC Biotech focuses on creating a pipeline of products that act as antagonists of the prostaglandin F2α (FP) receptor. Its key products include PDC31, a synthetic octapeptide designed as an allosteric modulator of the FP receptor, and the PDC41 Series, which offers a non-intravenous formulation for self-administration in primary dysmenorrhea. The company employs various delivery methods for its formulations, including nasal, sublingual, pulmonary, vaginal, and rectal suppositories. PDC Biotech has secured exclusive worldwide rights to a family of FP receptor antagonists from Theratechnologies Inc., further enhancing its position in the biopharmaceutical landscape.

Protagen

Venture Round in 2009
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Ganymed Pharmaceuticals

Series D in 2008
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Corimmun

Series A in 2008
Corimmun is a clinical drug development company based in Martinsried, near Munich, Germany. The company specializes in creating innovative therapeutics and diagnostics aimed at treating heart and vascular diseases, particularly those that currently have unmet medical needs. Corimmun's expertise encompasses the entire spectrum of drug development, from initial research through to commercialization, positioning it as a key player in the field of cardiovascular therapeutics.

Protagen

Venture Round in 2008
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

SuppreMol

Series B in 2008
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Protagen

Venture Round in 2008
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Isarna Therapeutics

Venture Round in 2007
Isarna Therapeutics is focused on developing selective TGF-β inhibitors aimed at treating ophthalmic diseases, fibrotic conditions, and cancer. The company is advancing a unique pipeline that includes novel oligonucleotides and combination therapies designed to enhance clinical responses and improve patient outcomes. Through its innovative approach, Isarna Therapeutics seeks to address significant unmet medical needs in these areas.

Sovicell

Series D in 2007
Sovicell specializes in offering advanced ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicology) products and services that facilitate the drug discovery process. The company provides bio-analytical kits designed to assess the pharmacokinetics of drug candidates and other test substances. These kits include tests for absorption, distribution, metabolism, excretion, and toxicity, enabling clients to swiftly obtain reliable and consistent pharmacokinetic data and predictions regarding potential side effects. Through its innovative solutions, Sovicell aims to enhance the efficiency and accuracy of drug development for its customers.

Biocrates Life Sciences

Series A in 2006
Biocrates Life Sciences AG is a biotechnology firm based in Innsbruck, Austria, specializing in targeted metabolic phenotyping solutions for the discovery and validation of biomarkers related to complex diseases. Founded in 2002, the company offers mass-spectrometry based kits and services that quantitatively analyze a wide range of endogenous metabolites, providing insights into disease pathways and metabolic signatures. Its products are applicable in various fields, including oncology, cardiovascular health, neurodegenerative disorders, and diabetes, among others. Biocrates' metabolomics platform features an automated sample preparation workflow and advanced software for sample management, data collection, and analysis, enabling the rapid identification of hundreds of metabolites. The company's solutions are distributed through authorized partners in multiple regions, including the Middle East, Europe, and Scandinavian countries, supporting both pre-clinical and clinical research efforts.

Protagen

Series B in 2006
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Isarna Therapeutics

Private Equity Round in 2005
Isarna Therapeutics is focused on developing selective TGF-β inhibitors aimed at treating ophthalmic diseases, fibrotic conditions, and cancer. The company is advancing a unique pipeline that includes novel oligonucleotides and combination therapies designed to enhance clinical responses and improve patient outcomes. Through its innovative approach, Isarna Therapeutics seeks to address significant unmet medical needs in these areas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.